Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro

Regenerative Medicine

Volumn 9, Issue 5, 2014, Pages 621-635

  Schnabel, Lauren V ^a   Abratte, Christian M ^b   Schimenti, John C ^b   Felippe, M Julia Bevilaqua ^b   Cassano, Jennifer M ^b   Southard, Teresa L ^b   Cross, Jessica A ^b   Fortier, Lisa A ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b Cornell University ^*  (United States)

Author keywords

allogeneic stem cell therapy; immunogenicity; immunomodulatory; induced pluripotent stem cell; mesenchymal stromal cell; transplantation medicine

Indexed keywords

CYTOKINE;

ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; COMPARATIVE STUDY; CULTURE TECHNIQUE; FEMALE; IMMUNOLOGY; IMMUNOMODULATION; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; PLURIPOTENT STEM CELL;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CYTOKINES; FEMALE; IMMUNOMODULATION; INDUCED PLURIPOTENT STEM CELLS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL;

EID: 84908674065     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.14.29     Document Type: Article

References (74)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006).
2. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007).
3. Takahashi K, Narita M, Yokura M et al. Human induced pluripotent stem cells on autologous feeders. PLoS ONE 4(12), e8067 (2009).
4. Sun N, Longaker MT, Wu JC. Human iPS cell-based therapy: considerations before clinical applications. Cell Cycle 9(5), 880-885 (2010).
5. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 471(7336), 58-62 (2011).
6. Tang C, Drukker M. Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations. Semin. Immunopathol. 33(6), 563-572 (2011).
7. Okita K, Nagata N, Yamanaka S. Immunogenicity of induced pluripotent stem cells. Circ. Res. 109(7), 720-721 (2011).
8. Drukker M. Immunological considerations for cell therapy using human embryonic stem cell derivatives. StemBook doi/10.3824/stembook.1.14.1 (2008) (Epub ahead of print).
9. de Almeida PE, Ransohoff JD, Nahid A et al. Immunogenicity of pluripotent stem cells and their derivatives. Circ. Res. 112(3), 549-561 (2013).
10. Jiang Z, Han Y, Cao X. Induced pluripotent stem cell (iPSCs) and their application in immunotherapy. Cell. Mol. Immunol. 11(1), 17-24 (2014).
11. Schnabel LV, Abratte CM, Schimenti JC et al. Genetic background affects induced pluripotent stem cell generation. Stem Cell. Res. Ther. 3(4), 30 (2012).
12. Fairchild PJ. The challenge of immunogenicity in the quest for induced pluripotency. Nat. Rev. Immunol. 10(12), 868-875 (2010).
13. Waterman RS, Tomchuck SL, Henkle SL et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE 5(4), e10088 (2010).
14. Bunnell BA, Betancourt AM, Sullivan DE. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell. Res. Ther. 1(5), 34 (2010).
15. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol. Ther. 17(6), 939-946 (2009).
16. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4), 1815-1822 (2005).
17. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 69(1), 1-9 (2007).
18. Stagg J, Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb. Exp. Pharmacol. (180), 45-66 (2007).
19. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum. Gene Ther. 21(12), 1641-1655 (2010).
20. Peister A, Mellad JA, Larson BL et al. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103(5), 1662-1668 (2004).
21. Baxter MA, Wynn RF, Jowitt SN et al. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. 22(5), 675-682 (2004).
22. Majors AK, Boehm CA, Nitto H et al. Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation. J. Orthop. Res. 15(4), 546-557 (1997).
23. Nasef A, Mathieu N, Chapel A et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84(2), 231-237 (2007).
24. Nasef A, Mazurier C, Bouchet S et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell. Immunol. 253(1-2), 16-22 (2008).
25. Nasef A, Zhang YZ, Mazurier C et al. Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int. J. Lab. Hematol. 31(1), 9-19 (2009).
26. Puissant B, Barreau C, Bourin P et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br. J. Haematol. 129(1), 118-129 (2005).
27. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10), 3838-3843 (2002).
28. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105(10), 4120-4126 (2005).
29. Plumas J, Chaperot L, Richard MJ et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia. 19(9), 1597-1604 (2005).
30. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102(10), 3837-3844 (2003).
31. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30(1), 42-48 (2002).
32. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103(12), 4619-4621 (2004).
33. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419), 1439-1441 (2004).
34. Eliopoulos N, Stagg J, Lejeune L et al. Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 106(13), 4057-4065 (2005).
35. Potian JA, Aviv H, Ponzio NM et al. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 171(7), 3426-3434 (2003).
36. Zangi L, Margalit R, Reich-Zeliger S et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 27(11), 2865-2874 (2009).
37. Griffin MD, Ryan AE, Alagesan S et al. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol. Cell Biol. 91(1), 40-51 (2013).
38. Nauta AJ, Westerhuis G, Kruisselbrink AB et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108(6), 2114-2120 (2006).
39. Badillo AT, Beggs KJ, Javazon EH et al. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol. Blood Marrow Transplant. 13(4), 412-422 (2007).
40. Jones EA, Kinsey SE, English A et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum. 46(12), 3349-3360 (2002).
41. Schnabel LV, Pezzanite LM, Antczak DF et al. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro. Stem Cell. Res. Ther. 5(1), 13 (2014).
42. Chan WK, Lau AS, Li JC et al. MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Exp. Hematol. 36(11), 1545-1555 (2008).
43. Romieu-Mourez R, Francois M, Boivin MN et al. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J. Immunol. 179(3), 1549-1558 (2007).
44. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 474, 212-216 (2011).
45. Guha P, Morgan JW, Mostoslavsky G et al. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12(4), 407-412 (2013).
46. Araki R, Uda M, Hoki Y et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494(7435), 100-104 (2013).
47. Chen HF, Yu CY, Chen MJ et al. Characteristic expression of major histocompatibility complex and immune privilege genes in human pluripotent stem cells and the derivatives. Cell Transplant. doi:10.3727/096368913X674639 (2013) (Epub ahead of print).
48. Suarez-Alvarez B, Rodriguez RM, Calvanese V et al. Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS ONE 5(4), e10192 (2010).
49. Pearl JI, Kean LS, Davis MM et al. Pluripotent stem cells: immune to the immune system? Sci. Transl. Med. 4(164), 164ps25 (2012).
50. Kadereit S, Trounson A. In vitro immunogenicity of undifferentiated pluripotent stem cells (PSC) and derived lineages. Semin. Immunopathol. 33(6), 551-562 (2011).
51. Bonde S, Zavazava N. Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells 24(10), 2192-2201 (2006).
52. Kaneko S, Yamanaka S. To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell 12(4), 385-386 (2013).
53. Pearl JI, Lee AS, Leveson-Gower DB et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 8(3), 309-317 (2011).
54. Yachimovich-Cohen N, Even-Ram S, Shufaro Y et al. Human embryonic stem cells suppress T cell responses via arginase I-dependent mechanism. J. Immunol. 184(3), 1300-1308 (2010).
55. Mohib K, Allan D, Wang L. Human embryonic stem cell-extracts inhibit the differentiation and function of monocyte-derived dendritic cells. Stem Cell.Rev. 6(4), 611-621 (2010).
56. Mohib K, AlKhamees B, Zein HS et al. Embryonic stem cell-derived factors inhibit T effector activation and induce T regulatory cells by suppressing PKC-theta activation. PLoS ONE 7(3), e32420 (2012).
57. Nagy K, Sung HK, Zhang P et al. Induced pluripotent stem cell lines derived from equine fibroblasts. Stem Cell. Rev. 7(3), 693-702 (2011).
58. Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res. Ther. 9(1), 204 (2007).
59. Meirelles Lda S, Nardi NB. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br. J. Haematol. 123(4), 702-711 (2003).
60. Baddoo M, Hill K, Wilkinson R et al. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J. Cell. Biochem. 89(6), 1235-1249 (2003).
61. Cieri N, Camisa B, Cocchiarella F et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121(4), 573-584 (2013).
62. Lu SY, Liu KY, Liu DH et al. High frequencies of CD62L(+) naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation. Clin. Exp. Immunol. 165(2), 264-277 (2011).
63. Chang YJ, Zhao XY, Huo MR et al. Expression profiles of adhesion molecules on naive T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. Transpl. Immunol. 21(4), 228-233 (2009).
64. Chang YJ, Zhao XY, Huo MR et al. Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. J. Clin. Immunol. 29(5), 696-704 (2009).
65. Kruisbeek AM. Isolation of mouse mononuclear cells. Curr. Protoc. Immunol. 39, 3.1.1-3.1.5 (2001).
66. Kruisbeek AM, Shevach E, Thornton AM. Proliferative assays for T cell function. Curr. Protoc. Immunol. 60, 3.12.1-3.12.20 (2004).
67. Muul LM, Heine G, Silvin C et al. Measurement of proliferative responses of cultured lymphocytes. Curr. Protoc. Immunol. Chapter 7, Unit 7.10 (2011).
68. Aladjem MI, Spike BT, Rodewald LW et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr. Biol. 8(3), 145-155 (1998).
69. You Y, Browning VL, Schimenti JC. Generation of radiation-induced deletion complexes in the mouse genome using embryonic stem cells. Methods 13(4), 409-421 (1997).
70. You Y, Bergstrom R, Klemm M et al. Chromosomal deletion complexes in mice by radiation of embryonic stem cells. Nat. Genet. 15(3), 285-288 (1997).
71. Pellegata NS, Antoniono RJ, Redpath JL et al. DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc. Natl Acad. Sci. USA 93(26), 15209-15214 (1996).
72. Xu J, Wang F, Tang Z et al. Role of leukaemia inhibitory factor in the induction of pluripotent stem cells in mice. Cell Biol. Int. 34(8), 791-797 (2010).
73. Koch CA, Geraldes P, Platt JL. Immunosuppression by embryonic stem cells. Stem Cells 26(1), 89-98 (2008).
74. DelaRosa O, Lombardo E. Modulation of adult mesenchymal stem cells activity by Toll-like receptors: implications on therapeutic potential. Mediators Inflamm. 2010, 865601 (2010).